Event Type
Disclosure
Voluntary
Variant
8-K
. Other Events . On January 13, 2026, Fortress Biotech, Inc. (the “ Company ”) issued a press release announcing that the U.S. Food and Drug Administration (“
. Financial Statements and Exhibits . (d) Exhibits. The following exhibit is furnished herewith: 99 Exhibit Number Description 99.1 Press Release of For